What Do Clinical Trial Phases Actually Mean? A Newcomer's Guide to Phase 1, 2, and 3

If you've spent any time researching stem cell therapy or cancer immunotherapy, you've probably run into phrases like “currently in a Phase 1 trial” or “FDA-approved.” These sound similar, but they describe very different things — one is a hypothesis still being tested, the other is a treatment that has cleared years of rigorous, independent scrutiny. This article walks through what each clinical trial phase actually measures, how many patients are typically involved, why most experimental cell and gene therapies never make it all the way through, and why understanding this pipeline is one of the single most useful tools a patient can have when evaluating a stem cell clinic's claims or an immunotherapy option.

The Pipeline, Start to Finish

Before a new cell therapy or drug is ever tested in a clinical trial, it goes through preclinical research — lab and animal studies that build the case for safety and biological plausibility. If that data is promising, the developer files an Investigational New Drug (IND) application with the FDA, which is reviewed under Institutional Review Board (IRB) oversight and requires informed consent from every participant, before any human testing can legally begin. Only then does a candidate therapy enter Phase 1, followed — if it survives — by Phase 2, Phase 3, FDA review, and finally Phase 4 (post-approval monitoring). Some programs also include an exploratory “Phase 0” (now often called Early Phase 1) involving very small numbers of participants and sub-therapeutic “microdoses,” used mainly to see how a compound behaves in the human body before committing to a full Phase 1 program, according to the NIH's NCATS glossary.

What Each Phase Actually Tests

Phase 1 asks: Is this safe, and what's a tolerable dose? According to the FDA, Phase 1 trials typically enroll 20 to 100 people (the National Cancer Institute puts oncology Phase 1 trials closer to 15–30 participants) and run for several months, focused almost entirely on safety, side effects, and dosing — not on whether the treatment works.

Phase 2 asks: Does this show a real effect, and is it still safe? These trials involve up to several hundred people with the condition being studied (NCI cites roughly 50–100 for cancer trials), running from several months to two years. For an immunotherapy or cell therapy, this is often where researchers first look for actual tumor shrinkage or immune response — but by FDA's tracking, only about a third of drugs that reach Phase 2 make it to Phase 3.

Phase 3 asks: Does this work better than what we already have? These are the large, often randomized, controlled trials — 300 to 3,000 participants per the FDA, sometimes several thousand for cancer studies per NCI — that directly compare the new treatment against standard-of-care therapy. This is the evidence base regulators use to decide whether a treatment is ready for approval, and even at this late stage, historically only about 25–30% of Phase 3 candidates proceed to approval.

Phase 4 happens after approval, monitoring large, real-world patient populations for long-term safety and effectiveness that smaller trials couldn't capture.

Why Most Cell Therapies Never Finish the Pipeline

It's genuinely difficult for any experimental therapy to cross the finish line — this isn't unique to stem cells or immunotherapy. Industry-wide, roughly 90% of drug candidates that enter clinical trials fail to reach approval, according to the New York Stem Cell Foundation, often because the biological target wasn't quite right, the trial couldn't find a reliable way to measure benefit, or the patient population studied didn't generalize to the broader disease. CAR-T and other engineered cell therapies face their own added hurdles — cells that don't persist long enough in the body, tumors that develop resistance mechanisms, or manufacturing failures that keep a product from ever reaching a patient, as researchers at Memorial Sloan Kettering and elsewhere have documented. This is precisely why a therapy being “in trials” is a meaningful, hopeful step — but not a guarantee of anything.

What “FDA-Approved” Actually Requires

This is the crux of it: FDA approval means a product has completed the full pipeline — typically Phase 1 through Phase 3 — and that an independent FDA review has concluded the data show the treatment is both safe and effective for a specific, defined use. It is a genuinely high bar, and the FDA's own safety communications are explicit that products marketed outside this framework, including many stem cell and exosome products sold at clinics, have not gone through that review at all — the agency has stated plainly that “there are currently no FDA-approved exosome products” and has issued warnings after unapproved exosome treatments caused serious infections. A treatment sitting in an early clinical trial, by contrast, has an active IND, IRB oversight, and informed consent protections — real regulatory guardrails — but its safety and effectiveness are still being established, not settled.

Why This Distinction Matters When You're Evaluating a Clinic

When a stem cell clinic advertises a treatment as “clinically studied” or “FDA-registered,” ask which of these stages it's actually describing. A product can be legitimately enrolled in a small Phase 1 safety study and still be marketed with language that implies far more certainty than the data supports. Knowing the difference between “we're testing whether this is safe” (Phase 1), “we're testing whether it works” (Phase 2), “we're proving it works better than the alternative” (Phase 3), and “regulators have reviewed the full case and approved it” gives you a concrete framework for asking the clinic pointed questions: What phase is this therapy in? Is there an active IND? Is this the same product studied in the trial, or a variation?

There is real, warranted encouragement here too. Pathways like the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, established under the 21st Century Cures Act, and accelerated approval (which can authorize a drug based on a surrogate endpoint for a serious unmet need, with confirmatory trials still required afterward) exist specifically to help promising cell and gene therapies reach patients faster without skipping the underlying safety and efficacy standard. And the pipeline does produce real wins for exactly this field: Kymriah (tisagenlecleucel), the first FDA-approved CAR-T cell therapy, was approved in August 2017 after a pivotal trial of 63 children and young adults with relapsed leukemia showed an 83% remission rate within three months — a genuine, hard-won success story that started, like every other candidate, in a small Phase 1 safety trial.

Bottom Line

Clinical trial phases exist to answer, in escalating order of rigor, whether a new stem cell or immunotherapy treatment is safe, whether it works, and whether it works better than what's already available — and only a small fraction of candidates that enter this pipeline ever reach FDA approval. That's not a reason for cynicism; it's the reason approved therapies like Kymriah are trustworthy in the first place, and it's exactly why expedited pathways like RMAT and accelerated approval matter so much for patients waiting on promising cell therapies. When you're evaluating any stem cell or immunotherapy option, the single most protective question you can ask is simple: is this treatment approved, or is it still being tested — and if it's being tested, at what phase?